Dr. Tim Harris is a molecular biologist and biochemist. He startedwork in the biotech industry almost at its inception. He began hiscareer in 1974, working on animal viruses, and was one of the firstscientists to join the U.K. biotech company Celltech in 1981.Subsequently he spent nearly five years at Glaxo Group Research (nowGSK) in the United Kingdom as Director of Biotechnology.Tim has founded several biotech companies since moving to the UnitedStates in 1993 to be head of R&D at Sequana Therapeutics, a genomicscompany in San Diego.

He founded and ran SGX Pharmaceuticals (acquiredby Eli Lilly) and served briefly as the Chief Technology Officer (CTO)and Director of the Advanced Technology Program (ATP) at SAIC-Frederick,Inc. in Maryland. Latterly, Tim moved to Biogen as SVP TranslationalMedicine in 2011, before joining the haematology spinout Bioverativ, ashead of R&D in March 2017 before the company was acquired by Sanofi.Tim is presently a venture partner at SV Health Investors and activelyworks on behalf of several small biotechnology companies, some of whichhe founded. He has published more than 100 peer-reviewed research papersand reviews and has written many commentaries for BioCentury and otherindustry magazines.